2026-07-21T14:20:11Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/186862024-09-21T20:01:27Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927col_20.500.12105_16960

00925njm 22002777a 4500 dc Pérez-Belmonte, Luis M author Sanz-Cánovas, Jaime author García de Lucas, María D author Ricci, Michele author Avilés-Bueno, Beatriz author Cobos-Palacios, Lidia author Pérez-Velasco, Miguel A author López-Sampalo, Almudena author Bernal-López, M Rosa author Jansen-Chaparro, Sergio author Miramontes-González, José P author Gómez-Huelgas, Ricardo author 2022-06-24 The impact of glucagon-like peptide-1 receptor agonists on patients with heart failure has not been fully described. Our main objective was to evaluate the safety and clinical and glycemic efficacy of once-weekly semaglutide in obese patients with type 2 diabetes and heart failure. In this observational, retrospective, real-world study, we enrolled outpatients with type 2 diabetes, obesity, and heart failure who started semaglutide and were followed-up on at 3, 6, and 12 months. A total of 136 patients were included. From baseline to 12 months, there was a significant improvement on the Kansas City Cardiomyopathy Questionnaire total symptom score (59.0 ± 24.1 vs 79.9 ± 28.4 points, p In obese patients with type 2 diabetes and heart failure, the use of once-weekly semaglutide was safe and clinically efficacious, improving health and functional status. Nevertheless, more strong evidence on glucagon-like peptide-1 receptor agonists in heart failure is required. 10.3389/fendo.2022.851035 1664-2392 Frontiers in endocrinology http://hdl.handle.net/10668/20560 35813629 http://hdl.handle.net/20.500.12105/18686 health status heart failure obesity semaglutide type 2 diabetes Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice.